当前位置:首页 >英文主页 >中英对照 > 报告详情

艾意凯咨询:2026生物制药企业的制胜之道:L.E.K.洞察:创新、增长与核心竞争力研究报告(英文版)(117页).pdf

上传人: 1****1 编号:1124453 2026-02-13 117页 10.95MB

下载:

1、English EditionThe Biopharma Imperative L.E.K.Insights on Innovation,Growth,andCompetitive AdvantageForewordThis collection brings together a focused selection of L.E.K.Consultings perspectives on the forces reshaping life sciences and biopharma.The sector continues to push at the boundaries of scie

2、ntific possibility while navigating capital constraints,accelerating competition and rising expectations from patients,regulators and investors.The pieces included here examine those pressures with clarity and offer practical guidance on how leaders can respond with confidence.Our insights highlight

3、 the strategic consequences of rapid advances in areas such as radiotherapeutics,nextgeneration oncology partnerships,AI and quantum computing.We also explore the commercial realities facing organisations as they compete in fastmoving therapeutic markets,reassess portfolio priorities,raise R&D produ

4、ctivity and operate in a more selective funding environment.Across these topics,a consistent message emerges:competitive advantage will rest with organisations that pair scientific ambition with disciplined decisionmaking and operational focus.At L.E.K.,we help clients interpret change and convert i

5、t into decisive action.By distilling market signals,emerging opportunities and the pressure points that matter most,this collection offers leaders a clear view of what it takes to steer successfully through a period of structural shifts.Helen ChenGlobal Sector Co-Head for Healthcare Greater China Ma

6、naging PartnerI L.E.K.ConsultingContents?1.2.3.4.5.6.7.8.9.10.?ContentsAbout L.E.K.Consulting?11.12.13.?EXECUTIVE INSIGHTS?R&D productivity stands as one of the most critical issues for biopharma executives,as it directly addresses the ability to transform pipeline investments into tangible revenue

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **生物制药研发生产力**:大型药企研发效率更高,2015-2023年每10亿美元研发投入获批新分子实体(NME)数量更多,且获批药物峰值收入达10亿美元以上,显著高于小型公司。 2. **放射性药物供应链**:放射性药物生产涉及同位素生成、放射性标记、剂量制备和配送等复杂环节,需通过内部供应或CDMO(合同研发生产组织)保障供应安全。 3. **伴随诊断(CDx)策略**:生物制药公司应将CDx纳入早期开发规划,采用“默认包含”模式,并制定独立上市策略,以提升肿瘤治疗精准度和市场价值。 4. **行业协作与分工**:大型药企与小型生物科技公司需协同创新,前者提供商业化资源,后者聚焦早期研发,通过战略合作提升整体研发效率。
生物制药如何提升研发效率? 放射性药物供应链如何优化? 伴随诊断如何成功上市?
客服
商务合作
小程序
服务号
折叠